This course aims to help learners understand Thyroid Eye Disease (TED) and the new treatments available for it. The learning outcomes include grasping the causes, pathophysiology, and implications of TED, as well as recognizing the vision-threatening impairments associated with the disease. The course covers treatment options such as steroids, orbital radiation, biologic therapy, and surgery, emphasizing a multidisciplinary approach. The intended audience includes individuals interested in ophthalmology, endocrinology, and patient-centered care for thyroid eye disease. The teaching method involves a lecture format delivered by a medical expert specializing in ophthalmology and aesthetic eye surgery.
Overview
Syllabus
Intro
Thyroid Eye Disease: Understanding the Disease & New Treatments Andrea Lora Kossler, MD, FACS
OUTLINE
GRAVES DISEASE THE SYSTEMIC COMPONENTS
THYROID EYE DISEASE (TED)
AUTOIMMUNE DISEASE
KEY PLAYER TED: THE ORBITAL FIBROBLAST
TED PATHOPHYSIOLOGY
TED IS ASSOCIATED WITH SIGNIFICANT VISION-THREATENING IMPAIRMENTS
EYELID RETRACTION 911
DIPLOPIA (DOUBLE VISION) 43-51%
TED HAS BROAD IMPLICATIONS FOR PATIENTS' LIVES
MILD TED
LIMITED WINDOW FOR TREATMENT1-3
TREATMENT: MULTIDISCIPLINARY APPROACH
CASE 1: 67 YEAR OLD FEMALE WITH EYE REDNESS, SWELLING, & PAIN X 2 MONTHS
CURRENT MANAGEMENT OPTIONS FOR TED
STEROIDS WERE THE PREVIOUS GOLD STANDARD TREATMENT
MEDICAL THERAPY: ORBITAL RADIATION
VISION THREATENING TED
TREATMENT-COMPRESSIVE OPTIC NEUROPATHY
CASE 2: 45 YO MALE TED, PROPTOSIS OU, DOUBLE VISION, PAIN, SWELLING AND LOSS OF VISION
BIOLOGIC THERAPY
TEPROTUMUMAB RESPONSE
OPTIC (PHASE 3) PROSPECTIVE RANDOMIZED TRIAL
SURGERY IS CURRENTLY THE MAIN OPTION FOR FIBROTIC TED
27 FEMALE PROPTOSIS AND LAGOPHTHALMOS
EYELID CREASE INCISION
POST OP WEEK 3 SP LATERAL WALL DECOMPRESSION
CONCLUSION- THYROID EYE DISEASE
Taught by
Stanford Health Care
